Modelling the effects of cell-cycle heterogeneity on the response of a solid tumour to chemotherapy: Biological insights from a hybrid multiscale cellular automaton model

Journal of Theoretical Biology

Volumn 308, Issue , 2012, Pages 1-19

  Powathil, Gibin G ^a   Gordon, Kirsty E ^a   Hill, Lydia A ^a,b   Chaplain, Mark A J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Cell cycle; Cellular automaton; Chemotherapy; Hybrid multiscale model; Hypoxia

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOLACTOL; OXYGEN; PACLITAXEL; ROSCOVITINE;

CELLULAR AUTOMATON; CHEMOTHERAPY; HYPOXIA; NUMERICAL MODEL; TUMOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOMATION; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL HETEROGENEITY; CELLULAR DISTRIBUTION; DIFFUSION COEFFICIENT; DRUG DIFFUSION; HYBRID CELL; INTRACELLULAR SIGNALING; MOLECULAR EVOLUTION; OXYGEN TRANSPORT; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL COUNT; CELL CYCLE; COMPUTER SIMULATION; DIFFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYBRID CELLS; INTRACELLULAR SPACE; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS; OXYGEN; TIME FACTORS;

EID: 84861994004     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2012.05.015     Document Type: Article

References (70)

1. Agur Z., Hassin R., Levy S. Optimizing chemotherapy scheduling using local search heuristics. Oper. Res. 2006, 54(September-October (5)):829-846.
2. Alarcon T., Byrne H.M., Maini P.K. A cellular automaton model for tumour growth in inhomogeneous environment. J. Theor. Biol. 2003, 225(November):257-274.
3. Alarcon T., Byrne H.M., Maini P.K. A mathematical model of the effects of hypoxia on the cell-cycle of normal and cancer cells. J. Theor. Biol. 2004, 229(August):395-411.
4. Alarcon T., Byrne H.M., Maini P.K. A multiple scale model for tumour growth. Multiscale Model. Sim. 2005, 3:440-475.
5. Altinok A., Levi F., Goldbeter A. A cell cycle automaton model for probing circadian patterns of anticancer drug delivery. Adv. Drug Deliv. Rev. 2007, 59(August):1036-1053.
6. Anderson A.R., Chaplain M.A. Continuous and discrete mathematical models of tumor-induced angiogenesis. Bull. Math. Biol. 1998, 60(September):857-899.
7. Anderson A.R., Rejniak K.A., Gerlee P., Quaranta V. Microenvironment driven invasion: a multiscale multimodel investigation. J. Math. Biol. 2009, 58(April):579-624.
8. Bailar J.C., Gornik H.L. Cancer undefeated. N. Engl. J. Med. 1997, 336(May):1569-1574.
9. Bekkal Brikci F., Clairambault J., Ribba B., Perthame B. An age-and-cyclin-structured cell population model for healthy and tumoral tissues. J. Math. Biol. 2008, 57(July):91-110.
10. Byrne H.M. Dissecting cancer through mathematics: from the cell to the animal model. Nat. Rev. Cancer 2010, 10(March):221-230.
11. Chaplain M., Anderson A. Mathematical modelling of tumour-induced angiogenesis: network growth and structure. Cancer Treat. Res. 2004, 117:51-75.
12. Clairambault J. A step toward optimization of cancer therapeutics. Physiologically based modeling of circadian control on cell proliferation. IEEE Eng. Med. Biol. Mag. 2008, 27:20-24.
13. Dasu A., Toma-Dasu I., Karlsson M. Theoretical simulation of tumour oxygenation and results from acute and chronic hypoxia. Phys. Med. Biol. 2003, 48(September):2829-2842.
14. Deep G., Agarwal R. New combination therapies with cell-cycle agents. Curr. Opin. Investig. Drugs 2008, 9(June):591-604.
15. Deisboeck T.S., Wang Z., Macklin P., Cristini V. Multiscale cancer modeling. Annu. Rev. Biomed. Eng. 2011, 13(August):127-155.
16. Dormann S., Deutsch A. Modeling of self-organized avascular tumor growth with a hybrid cellular automaton. In Silico Biol. (Gedrukt) 2002, 2:393-406.
17. Douglas R.M., Haddad G.G. Genetic models in applied physiology: invited review: effect of oxygen deprivation on cell cycle activity: a profile of delay and arrest. J. Appl. Physiol. 2003, 94(May):2068-2083.
18. Frieboes H.B., Edgerton M.E., Fruehauf J.P., Rose F.R., Worrall L.K., Gatenby R.A., Ferrari M., Cristini V. Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Res. 2009, 69(May):4484-4492.
19. Gardner L.B., Li Q., Park M.S., Flanagan W.M., Semenza G.L., Dang C.V. Hypoxia inhibits G1/S transition through regulation of p27 expression. J. Biol. Chem. 2001, 276(March):7919-7926.
20. Garrett M.D., Fattaey A. CDK inhibition and cancer therapy. Curr. Opin. Genet. Dev. 1999, 9(February):104-111.
21. Gatenby R.A. A change of strategy in the war on cancer. Nature 2009, 459(May):508-509.
22. Gatenby R.A., Silva A.S., Gillies R.J., Frieden B.R. Adaptive therapy. Cancer Res. 2009, 69(June):4894-4903.
23. Gelderblom H., Baker S.D., Zhao M., Verweij J., Sparreboom A. Distribution of paclitaxel in plasma and cerebrospinal fluid. Anticancer Drugs 2003, 14(June):365-368.
24. Gerard C., Goldbeter A. Temporal self-organization of the cyclin/Cdk network driving the mammalian cell cycle. Proc. Natl. Acad. Sci. U.S.A. 2009, 106(December):21643-21648.
25. Gerlee P., Anderson A.R. An evolutionary hybrid cellular automaton model of solid tumour growth. J. Theor. Biol. 2007, 246(June):583-603.
26. Goda N., Dozier S.J., Johnson R.S. HIF-1 in cell cycle regulation, apoptosis, and tumor progression. Antioxid. Redox Signal. 2003, 5(August):467-473.
27. Goda N., Ryan H.E., Khadivi B., McNulty W., Rickert R.C., Johnson R.S. Hypoxia-inducible factor 1α is essential for cell cycle arrest during hypoxia. Mol. Cell. Biol. 2003, 23(January):359-369.
28. Goldbeter A. A minimal cascade model for the mitotic oscillator involving cyclin and cdc2 kinase. Proc. Natl. Acad. Sci. U.S.A. 1991, 88(October):9107-9111.
29. Gordon, K., 2006. Mathematical Modelling of Cell-cycle-dependent Chemotherapy Drugs-implications for Cancer Treatment. Ph.D. Thesis, University of Dundee, Dundee.
30. Hlatky L., Alpen E.L. Two-dimensional diffusion limited system for cell growth. Cell Tissue Kinet. 1985, 18(November):597-611.
31. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307(January):58-62.
32. Jain R.K., Tong R.T., Munn L.L. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. 2007, 67(March):2729-2735.
33. Kansal A.R., Torquato S., Harsh G.R., Chiocca E.A., Deisboeck T.S. Cellular automaton of idealized brain tumor growth dynamics. BioSystems 2000, 55(February):119-127.
34. Konerding M.A., Malkusch W., Klapthor B., van Ackern C., Fait E., Hill S.A., Parkins C., Chaplin D.J., Presta M., Denekamp J. Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts. Br. J. Cancer 1999, 80(May):724-732.
35. Kraynak M.A. Pharmaceutical aspects of docetaxel. Am. J. Health Syst. Pharm. 1997, 54(December):7-10.
36. Levin V.A., Patlak C.S., Landahl H.D. Heuristic modeling of drug delivery to malignant brain tumors. J. Pharmacokinet. Biopharm. 1980, 8(June):257-296.
37. Lowengrub J.S., Frieboes H.B., Jin F., Chuang Y.L., Li X., Macklin P., Wise S.M., Cristini V. Nonlinear modelling of cancer: bridging the gap between cells and tumours. Nonlinearity 2010, 23:R1-R9.
38. Macklin P., Edgerton M.E., Thompson A.M., Cristini V. Patient-calibrated agent-based modelling of ductal carcinoma in situ (dcis): from microscopic measurements to macroscopic predictions of clinical progression. J. Theor. Biol. 2012, 301:122-140.
39. Masson E., Zamboni W.C. Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes. Clin. Pharmacokinet. 1997, 32(April):324-343.
40. Matzavinos A., Kao C.Y., Green J.E., Sutradhar A., Miller M., Friedman A. Modeling oxygen transport in surgical tissue transfer. Proc. Natl. Acad. Sci. U.S.A. 2009, 106(July):12091-12096.
41. Moreira J., Deutsch A. Cellular automaton models of tumor development: a critical review. Adv. Complex Syst. 2002, 5(02):247-267.
42. Novak B., Tyson J.J. Modelling the controls of the eukaryotic cell cycle. Biochem. Soc. Trans. 2003, 31(December):1526-1529.
43. Novak B., Tyson J.J. A model for restriction point control of the mammalian cell cycle. J. Theor. Biol. 2004, 230(October):563-579.
44. Owen M.R., Byrne H.M., Lewis C.E. Mathematical modelling of the use of macrophages as vehicles for drug delivery to hypoxic tumour sites. J. Theor. Biol. 2004, 226(February):377-391.
45. Owen M.R., Alarcon T., Maini P.K., Byrne H.M. Angiogenesis and vascular remodelling in normal and cancerous tissues. J. Math. Biol. 2009, 58(April):689-721.
46. Pasquier E., Kavallaris M., Andre N. Metronomic chemotherapy: new rationale for new directions. Nat. Rev. Clin. Oncol. 2010, 7(August):455-465.
47. Patel A.A., Gawlinski E.T., Lemieux S.K., Gatenby R.A. A cellular automaton model of early tumor growth and invasion. J. Theor. Biol. 2001, 213(December):315-331.
48. Perfahl H., Byrne H.M., Chen T., Estrella V., Alarcon T., Lapin A., Gatenby R.A., Gillies R.J., Lloyd M.C., Maini P.K., Reuss M., Owen M.R. Multiscale modelling of vascular tumour growth in 3D: the roles of domain size and boundary conditions. PLoS ONE 2011, 6:e14790.
49. Perry M.C. The Chemotherapy Source Book 1996, Williams and Wilkins, Baltimore.
50. Pouyssegur J., Dayan F., Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441(May):437-443.
51. Powathil G., Kohandel M., Milosevic M., Sivaloganathan S. Modeling the spatial distribution of chronic tumor hypoxia: implications for experimental and clinical studies. Comput. Math. Methods Med. 2012, 2012:410602.
52. Reece P.A., Stafford I., Abbott R.L., Anderson C., Denham J., Freeman S., Morris R.G., Gill P.G., Olweny C.L. Two-versus 24-hour infusion of cisplatin: pharmacokinetic considerations. J. Clin. Oncol. 1989, 7(February):270-275.
53. Ribba, B.T., Alarcon, T., Marron, K., Maini, P.K., Agur, Z., 2004. The use of hybrid cellular automaton models for improving cancer therapy. In: Lecture Notes in Computer Science, vol. 3305, pp. 444-453.
54. Ribba B., Colin T., Schnell S. A multiscale mathematical model of cancer, and its use in analyzing irradiation therapies. Theor. Biol. Med. Model. 2006, 3:7.
55. Ribba B., You B., Tod M., Girard P., Tranchand B., Trillet-Lenoir V., Freyer G. Chemotherapy may be delivered based on an integrated view of tumour dynamics. IET Syst. Biol. 2009, 3:180-190.
56. Rijken P.F., Bernsen H.J., Peters J.P., Hodgkiss R.J., Raleigh J.A., van der Kogel A.J. Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a quantitative multi-parameter analysis. Int. J. Radiat. Oncol. Biol. Phys. 2000, 48(September):571-582.
57. Schwartz G.K., Shah M.A. Targeting the cell cycle: a new approach to cancer therapy. J. Clin. Oncol. 2005, 23(December):9408-9421.
58. Serini G., Ambrosi D., Giraudo E., Gamba A., Preziosi L., Bussolino F. Modeling the early stages of vascular network assembly. EMBO J. 2003, 22(April):1771-1779.
59. Shah M.A., Schwartz G.K. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin. Cancer Res. 2001, 7(August):2168-2181.
60. Shochat E., Hart D., Agur Z. Using computer simulations for evaluating the efficacy of breast cancer chemotherapy protocols. Math. Models Methods Appl. Sci. 1999, 9(June (4)):599-615.
61. Silva A.S., Gatenby R.A. A theoretical quantitative model for evolution of cancer chemotherapy resistance. Biol. Direct 2010, 5:25.
62. Sinek J.P., Sanga S., Zheng X., Frieboes H.B., Ferrari M., Cristini V. Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation. J. Math. Biol. 2009, 58(April):485-510.
63. Stamper I.J., Owen M.R., Maini P.K., Byrne H.M. Oscillatory dynamics in a model of vascular tumour growth-implications for chemotherapy. Biol. Direct 2010, 5:27.
64. Turner S., Sherratt J.A. Intercellular adhesion and cancer invasion: a discrete simulation using the extended Potts model. J. Theor. Biol. 2002, 216(May):85-100.
65. Tyson J.J., Novak B. Regulation of the eukaryotic cell cycle: molecular antagonism, hysteresis, and irreversible transitions. J. Theor. Biol. 2001, 210(May):249-263.
66. Vaupel P. Oxygenation of human tumors. Strahlenther. Onkol. 1990, 166(June):377-386.
67. Vaupel P., Hockel M. Blood supply, oxygenation status and metabolic micromilieu of breast cancers: characterization and therapeutic relevance. Int. J. Oncol. 2000, 17(November):869-879.
68. Vita M., Abdel-Rehim M., Olofsson S., Hassan Z., Meurling L., Siden A., Siden M., Pettersson T., Hassan M. Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat. Eur. J. Pharm. Sci. 2005, 25(May):91-103.
69. Weinberg R. The Biology of Cancer 2006, Garland Science, Taylor and Francis Group.
70. Zalatnai A. Review: potential role of cell cycle synchronizing agents in combination treatment modalities of malignant tumors. In Vivo 2005, 19:85-91.